Halozyme (HALO) Prices 6.8M Offering at $10.61/Share
Down)
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at a price to the public of $10.61 per share. The offering is expected to settle and close on February 15, 2012, subject to customary closing conditions. Barclays Capital Inc. is the sole book-running manager of the offering, and Halozyme has granted them a thirty (30) day option to purchase up to 1,020,000 shares of common stock. Halozyme intends to use the net proceeds from the offering to build commercial inventory for anticipated product launches, fund research and development of proprietary programs, and for general corporate purposes.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Euroseas (ESEA) commences 13.9M rights offering
- American Capital Mortgage (MTGE) Prices 11M Offering; Sees Gross Proceeds of $253M
- Heritage Oaks Bancorp (HEOP) pays deferred interest on TARP preferreds
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
